Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Navigation Helps At-Risk Patients Catch Breast Cancer Earlier

      March 6, 2020
      By Brielle Benyon
      Article

      Enhanced navigation led some high-risk patients to an earlier breast cancer diagnosis, according to recent research.

      While national guidelines recommend that women at an increased risk of breast cancer undergo additional screening and get extra services, many individuals do not adhere to these recommendations simply because they are unaware of their risk.

      In an attempt to remedy this problem, researchers from Stamford Hospital in Stamford, Connecticut employed a lay navigator to educate patients about the additional services. They recently presented their findings at the 37th Annual Miami Breast Cancer Conference.

      “We tracked patient acceptance of referral for risk reduction counseling, to medical oncology for consideration of chemoprevention, to genetic counseling when indicated as well as their willingness to participate in enhanced surveillance,” the authors wrote.

      A total of 3,792 high-risk patients (as determined by the NCI Gail Model and version 8 of the Tyrer Cuzick Risk Assessment Model) were identified via mammography. To be determined high-risk, women had a 5-year risk greater than 1.67% and a lifetime risk of 20% or higher.

      More than half (52%) who were not previously participating in the high-risk program were contacted by phone, and as a result, 398 (20%) made an appointment. At the time of the study’s end, 13 patients accepted referral to medical oncology, while 39 saw genetic counselors.

      To-date, there were 14 patients who agreed to all genetic testing, and three of them had a deleterious mutation, such as BRCA, PALB2, NBN, that put them at higher risk for cancer. One patient who had a BRCA mutation even chose to have a bilateral prophylactic mastectomy.

      Additionally, 133 patients were prescribed an MRI. At the time of presentation, 71 were completed, and 19 also needed an image-guided biopsy. Altogether, three cancers were diagnosed: two patients had ductal carcinoma in situ (DCIS) 1 patient was diagnosed with invasive lobular carcinoma.

      “A lay navigator was effective in identifying high-risk patients and successfully guiding them to a comprehensive high-risk breast program,” the authors wrote. “As a result, these patients benefited from enhanced surveillance as indicated and risk appropriate consultations.”

      Reference:

      Burgwardt N, O’Riordan M, Baird C, et. al. Enhanced Navigation Improves Adherence to Recommended Guidelines by Woman at an Increased Risk of Breast Cancer. Presented at: 37th Annual Miami Breast Cancer Conference. Miami, Florida. March 5-8, 2020.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      3 experts in this video
      3 experts in this video
      3 experts in this video
      3 experts in this video
      3 experts in this video
      3 experts in this video
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a woman with shoulder-length black hair wearing headphones and a white sweater
      Photo of a woman with brown hair and bangs, surrounded by a blue border
      Related Content

      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Line illustration of a breast

      Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

      Kristi Rosa
      May 31st 2025
      Article

      Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.


      Anatomical rendering of a breast with a tumor

      Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

      Caroline Seymour
      May 31st 2025
      Article

      Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

      Related Content

      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Line illustration of a breast

      Sacituzumab Govitecan/Pembrolizumab Backed as New SOC in PD-L1+ TNBC

      Kristi Rosa
      May 31st 2025
      Article

      Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.


      Anatomical rendering of a breast with a tumor

      Vepdegestrant Increases PFS in ESR1-Mutated ER+/HER2- Breast Cancer

      Caroline Seymour
      May 31st 2025
      Article

      Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

      Latest Conference Coverage

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      Olanzapine May Reduce Nausea, Vomiting From Radiation

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.